Sec. 44301. Expanding and clarifying the exclusion for orphan drugs under the Drug Price Negotiation Program
171 words·~1 min read·
/bill/119/hr/1/rh/section-44301A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Section 1192(e) of the Social Security Act ( 42 U.S.C. 1320f–1(e) ) is amended— in paragraph (1), by adding at the end the following new subparagraph: In calculating the amount of time that has elapsed with respect to the approval of a drug or licensure of a biological product under subparagraph (A)(ii) and subparagraph (B)(ii), respectively, the Secretary shall not take into account any period during which such drug or product was a drug described in paragraph (3)(A). ; and in paragraph (3)(A)— by striking only one rare disease or condition and inserting one or more rare diseases or conditions ; and by striking such disease or condition and inserting one or more rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act) .
The amendments made by subsection
(a)shall apply with respect to initial price applicability years (as defined in section 1191(b) of the Social Security Act ( 42 U.S.C. 1320f(b) )) beginning on or after January 1, 2028.
Connectionstraces to 1
Traces to 1 document
U.S. Code
1 reference not yet in our index
- 42 USC 1320f–1(e)
Citation graph
cites case law
Sec. 44301
Expanding and clarifying the exclusion for orphan drugs under the Drug Price Negotiation Program
Cite42 USC 1320f–1(e)
Cites 2Cited by 0 across 0 sources